Last reviewed · How we verify
Edecrin (ETHACRYNIC ACID)
Ethacrynic Acid (Edecrin), marketed by Bausch Health, is a diuretic used primarily for the treatment of edema in congestive heart failure. Its unique mechanism of action, inhibiting glutathione S-transferase P to reduce sodium and chloride reabsorption in the kidneys, sets it apart from other diuretics in its class. The primary risk is the expiration of the key composition patent in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | ETHACRYNIC ACID |
|---|---|
| Sponsor | Bausch Health |
| Drug class | Loop Diuretic [EPC] |
| Target | Glutathione S-transferase P |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| First approval | 1967 |
Approved indications
- Edema in Congestive Heart Failure
- Edema in Cirrhosis of the Liver
- Edema in Renal Disease
- Ascites Due to Malignancy
- Idiopathic Edema
- Lymphedema
- Congenital Heart Disease in Pediatric Patients
- Nephrotic Syndrome in Pediatric Patients
- Acute Pulmonary Edema
- Impaired Gastrointestinal Absorption
Common side effects
- Diarrhea
- Gastrointestinal bleeding
- Acute pancreatitis
- Jaundice
- Abnormal liver function tests
- Agranulocytosis
- Severe neutropenia
- Thrombocytopenia
- Henoch-Schonlein purpura
- Deafness
- Tinnitus
- Vertigo
Drug interactions
- Lithium
- Aminoglycoside antibiotics
- Cephalosporin antibiotics
- Warfarin
- Non-steroidal anti-inflammatory agents
Key clinical trials
- Pharmacokinetics of Drugs Administered to Children
- ACEI or ARB and COVID-19 Severity and Mortality in US Veterans
- Ethacrynic Acid Elimination in Non-Muscle Invasive Bladder Cancer Patients Undergoing Transurethral Resection (PHASE1)
- Novel Drug Delivery Technique Via Retroject Device (PHASE1,PHASE2)
- Furosemide Versus Ethacrynic Acid in Children With Congenital Heart Disease (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Edecrin CI brief — competitive landscape report
- Edecrin updates RSS · CI watch RSS
- Bausch Health portfolio CI